242 related articles for article (PubMed ID: 22525969)
21. Testing for qualitative heterogeneity: An application to composite endpoints in survival analysis.
Oulhaj A; El Ghouch A; Holman RR
Stat Methods Med Res; 2019 Jan; 28(1):151-169. PubMed ID: 28670972
[TBL] [Abstract][Full Text] [Related]
22. Analysis of a binary composite endpoint with missing data in components.
Quan H; Zhang D; Zhang J; Devlamynck L
Stat Med; 2007 Nov; 26(26):4703-18. PubMed ID: 17431851
[TBL] [Abstract][Full Text] [Related]
23. Some issues with composite endpoints in clinical trials.
Chi GY
Fundam Clin Pharmacol; 2005 Dec; 19(6):609-19. PubMed ID: 16313272
[TBL] [Abstract][Full Text] [Related]
24. Methods for the analysis of multiple endpoints in small populations: A review.
Ristl R; Urach S; Rosenkranz G; Posch M
J Biopharm Stat; 2019; 29(1):1-29. PubMed ID: 29985752
[TBL] [Abstract][Full Text] [Related]
25. Opportunities and challenges of clinical trials in cardiology using composite primary endpoints.
Rauch G; Rauch B; Schüler S; Kieser M
World J Cardiol; 2015 Jan; 7(1):1-5. PubMed ID: 25632312
[TBL] [Abstract][Full Text] [Related]
26. Power and sample size for clinical trials when efficacy is required in multiple endpoints: application to an Alzheimer's treatment trial.
Xiong C; Yu K; Gao F; Yan Y; Zhang Z
Clin Trials; 2005; 2(5):387-93. PubMed ID: 16317808
[TBL] [Abstract][Full Text] [Related]
27. A consistency-adjusted strategy for accommodating an underpowered primary endpoint.
Huque MF; Alosh M
J Biopharm Stat; 2012; 22(1):160-79. PubMed ID: 22204533
[TBL] [Abstract][Full Text] [Related]
28. Multiple-arm superiority and non-inferiority designs with various endpoints.
Chang M
Pharm Stat; 2007; 6(1):43-52. PubMed ID: 17323311
[TBL] [Abstract][Full Text] [Related]
29. Analysis strategies for adaptive designs with multiple endpoints.
Chang M; Chow SC
J Biopharm Stat; 2007; 17(6):1189-200. PubMed ID: 18027225
[TBL] [Abstract][Full Text] [Related]
30. A weighted combined effect measure for the analysis of a composite time-to-first-event endpoint with components of different clinical relevance.
Rauch G; Kunzmann K; Kieser M; Wegscheider K; König J; Eulenburg C
Stat Med; 2018 Feb; 37(5):749-767. PubMed ID: 29205425
[TBL] [Abstract][Full Text] [Related]
31. A reviewer's perspective on multiple endpoint issues in clinical trials.
Huque MF; Sankoh AJ
J Biopharm Stat; 1997 Nov; 7(4):545-64. PubMed ID: 9358328
[TBL] [Abstract][Full Text] [Related]
32. A new partition testing strategy for multiple endpoints.
Wang B; Cui X
Stat Med; 2012 Sep; 31(20):2151-68. PubMed ID: 22532094
[TBL] [Abstract][Full Text] [Related]
33. Some remaining challenges regarding multiple endpoints in clinical trials.
Snapinn S
Stat Med; 2017 Dec; 36(28):4441-4445. PubMed ID: 28664566
[TBL] [Abstract][Full Text] [Related]
34. Statistical power of multiplicity adjustment strategies for correlated binary endpoints.
Leon AC; Heo M; Teres JJ; Morikawa T
Stat Med; 2007 Apr; 26(8):1712-23. PubMed ID: 17252534
[TBL] [Abstract][Full Text] [Related]
35. A note on the power of Fisher's least significant difference procedure.
Meier U
Pharm Stat; 2006; 5(4):253-63. PubMed ID: 17128424
[TBL] [Abstract][Full Text] [Related]
36. Conditional power calculations for clinical trials with historical controls.
Korn EL; Freidlin B
Stat Med; 2006 Sep; 25(17):2922-31. PubMed ID: 16479548
[TBL] [Abstract][Full Text] [Related]
37. Post hoc analyses: after the facts.
Srinivas TR; Ho B; Kang J; Kaplan B
Transplantation; 2015 Jan; 99(1):17-20. PubMed ID: 25525920
[TBL] [Abstract][Full Text] [Related]
38. Opportunities and challenges of combined effect measures based on prioritized outcomes.
Rauch G; Jahn-Eimermacher A; Brannath W; Kieser M
Stat Med; 2014 Mar; 33(7):1104-20. PubMed ID: 24122841
[TBL] [Abstract][Full Text] [Related]
39. A convenient formula for sample size calculations in clinical trials with multiple co-primary continuous endpoints.
Sugimoto T; Sozu T; Hamasaki T
Pharm Stat; 2012; 11(2):118-28. PubMed ID: 22415870
[TBL] [Abstract][Full Text] [Related]
40. Statistical analysis for two-stage seamless design with different study endpoints.
Chow SC; Lu Q; Tse SK
J Biopharm Stat; 2007; 17(6):1163-76. PubMed ID: 18027223
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
